CR and, in particular, insulin/IGF1 inhibition slows down the cell cycle and thus global tumor growth, but at the same time attenuates responsiveness to innate immune pathways that would induce cancer stem-cell clearance, favoring their persistence. The gene discussed is IGF1; the disease is neoplasm.